Next Article in Journal
Role of B Cells in Breaking and Maintaining Tolerance to Clotting Factor VIII in Congenital and Acquired Hemophilia A
Next Article in Special Issue
Refolding Technologies for Antibody Fragments
Previous Article in Journal
Characterization Analysis of Human Anti-Ferritin Autoantibodies
Previous Article in Special Issue
Production of Single-Chain Variable-Fragments against Carbohydrate Antigens
Article

The Biotechnological Applications of Recombinant Single-Domain Antibodies are Optimized by the C-Terminal Fusion to the EPEA Sequence (C Tag)

1
Tumor target and therapeutic antibody-Identification Platform (TAb-IP), Institut Curie, 3-5 Impasse Reille, 75014 Paris, France
2
SIRIC INCa-DGOS-4654, Institut Curie, F-75248 Paris Cedex 05, France
3
CIC IGR Curie 1428, Institut Curie, F-75248 Paris Cedex 05, France
4
Dept. of Biomedical Sciences and Engineering, University of Nova Gorica (UNG), Glavni Trg 9-SI-5261, Vipava, Slovenia
*
Author to whom correspondence should be addressed.
Antibodies 2014, 3(2), 182-191; https://doi.org/10.3390/antib3020182
Received: 11 February 2014 / Revised: 18 March 2014 / Accepted: 20 March 2014 / Published: 2 April 2014
(This article belongs to the Special Issue Antibody Constructs)
We designed a vector for the bacterial expression of recombinant antibodies fused to a double tag composed of 6xHis and the EPEA amino acid sequence. EPEA sequence (C tag) is tightly bound by a commercial antibody when expressed at the C-term end of a polypeptide. The antigen is released in the presence of 2 M MgCl2. Consequently, constructs fused to the 6xHis-C tags can be purified by two successive and orthogonal affinity steps. Single-domain antibodies were produced either in the periplasmic or in the cytoplasmic space of E. coli. Surprisingly, the first affinity purification step performed using the EPEA-binding resin already yielded homogeneous proteins. The presence of the C tag did not interfere with the binding activity of the antibodies, as assessed by FACS and SPR analyses, and the C tag was extremely effective for immunoprecipitating HER2 receptor. Finally, the Alexa488-coupled anti-C tag allowed for simplification of FACS and IF analyses. These results show that a tag of minimal dimensions can be effectively used to improve the applicability of recombinant antibodies as reagents. In our hands, C tag was superior to His-tag in affinity purification and pull-down experiments, and practical in any other standard immune technique. View Full-Text
Keywords: antibody screening; cytoplasmic antibody expression; immunoprecipitation; nanobody; VHH; tandem affinity purification antibody screening; cytoplasmic antibody expression; immunoprecipitation; nanobody; VHH; tandem affinity purification
Show Figures

Figure 1

MDPI and ACS Style

Djender, S.; Beugnet, A.; Schneider, A.; De Marco, A. The Biotechnological Applications of Recombinant Single-Domain Antibodies are Optimized by the C-Terminal Fusion to the EPEA Sequence (C Tag). Antibodies 2014, 3, 182-191. https://doi.org/10.3390/antib3020182

AMA Style

Djender S, Beugnet A, Schneider A, De Marco A. The Biotechnological Applications of Recombinant Single-Domain Antibodies are Optimized by the C-Terminal Fusion to the EPEA Sequence (C Tag). Antibodies. 2014; 3(2):182-191. https://doi.org/10.3390/antib3020182

Chicago/Turabian Style

Djender, Selma, Anne Beugnet, Aurelie Schneider, and Ario De Marco. 2014. "The Biotechnological Applications of Recombinant Single-Domain Antibodies are Optimized by the C-Terminal Fusion to the EPEA Sequence (C Tag)" Antibodies 3, no. 2: 182-191. https://doi.org/10.3390/antib3020182

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop